---
document_datetime: 2025-12-02 04:56:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zegalogue.html
document_name: zegalogue.html
version: success
processing_time: 0.1065149
conversion_datetime: 2025-12-28 10:39:41.144206
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zegalogue

[RSS](/en/individual-human-medicine.xml/243528)

##### Authorised

This medicine is authorised for use in the European Union

dasiglucagon Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zegalogue](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zegalogue is used for treating severe hypoglycaemia (low blood glucose levels) in adults and children from 6 years of age who have diabetes mellitus.

Hypoglycaemia can occur when diabetes medicines cause glucose levels to fall too low. In severe cases, patients can faint or become unconscious, and they must be treated urgently to raise their glucose levels.

Zegalogue contains the active substance dasiglucagon.

Expand section

Collapse section

## How is Zegalogue used?

Zegalogue is given by injection under the skin in the lower abdomen, buttocks, thigh or outer upper arm as soon as signs of severe hypoglycaemia are recognised. If there is no response, an additional dose from another device may be given after 15 minutes.

Patients and their caregivers should receive information about the signs and symptoms of severe hypoglycaemia. As severe hypoglycaemia requires the help of others, the patient should be instructed to inform those around them about Zegalogue and how to use it.

The medicine can only be obtained with a prescription. For more information about using Zegalogue, see the package leaflet or contact your doctor or pharmacist.

## How does Zegalogue work?

The active substance in Zegalogue works in a similar way to a natural hormone in the body called glucagon. In patients with low levels of blood glucose, the medicine causes the liver to release stored glucose into the bloodstream, thereby reducing symptoms of hypoglycaemia.

## What benefits of Zegalogue have been shown in studies?

Three main studies showed that Zegalogue was effective at restoring blood glucose levels in patients with type 1 diabetes whose blood glucose levels were very low after insulin treatment.

In the first study in 168 adults, patients who had Zegalogue recovered in 10 minutes while those given placebo recovered in 40 minutes. There were similar results in a second study in 44 adults where patients who had Zegalogue recovered in 10 minutes while those who had placebo recovered after 35 minutes.

The third study involved 41 children from 6 years of age. In this study, patients who had Zegalogue also recovered in 10 minutes, while those on placebo recovered after 30 minutes.

## What are the risks associated with Zegalogue?

For the full list of side effects and restrictions with Zegalogue, see the package leaflet.

The most common side effects with Zegalogue (which may affect more than 1 in 10 people) include nausea (feeling sick) and vomiting. Another common side effect which may affect up to 1 in 10 people is headache.

Zegalogue must not be used in patients with phaeocromocytoma (a tumour in the adrenal glands).

## Why is Zegalogue authorised in the EU?

The main studies showed that Zegalogue was effective at restoring blood glucose levels in people with hypoglycaemia caused by insulin treatment. The side effects are considered acceptable. The European Medicines Agency therefore decided that Zegalogue 's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zegalogue?

The company that markets Zegalogue will provide healthcare professionals, patients and caregivers with educational materials, a leaflet and an instructional video, on how to use the medicine.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zegalogue have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zegalogue are continuously monitored. Suspected side effects reported with Zegalogue are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zegalogue

Zegalogue received a marketing authorisation valid throughout the EU on 24 July 2024.

Zegalogue - EPAR : Medicine overview

Reference Number: EMA/307646/2024

English (EN) (107.9 KB - PDF)

**First published:** 23/08/2024

[View](/en/documents/overview/zegalogue-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-298)

български (BG) (132.27 KB - PDF)

**First published:**

23/08/2024

[View](/bg/documents/overview/zegalogue-epar-medicine-overview_bg.pdf)

español (ES) (109.02 KB - PDF)

**First published:**

23/08/2024

[View](/es/documents/overview/zegalogue-epar-medicine-overview_es.pdf)

čeština (CS) (129.16 KB - PDF)

**First published:**

23/08/2024

[View](/cs/documents/overview/zegalogue-epar-medicine-overview_cs.pdf)

dansk (DA) (107.98 KB - PDF)

**First published:**

23/08/2024

[View](/da/documents/overview/zegalogue-epar-medicine-overview_da.pdf)

Deutsch (DE) (111.72 KB - PDF)

**First published:**

23/08/2024

[View](/de/documents/overview/zegalogue-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.75 KB - PDF)

**First published:**

23/08/2024

[View](/et/documents/overview/zegalogue-epar-medicine-overview_et.pdf)

ελληνικά (EL) (129.85 KB - PDF)

**First published:**

23/08/2024

[View](/el/documents/overview/zegalogue-epar-medicine-overview_el.pdf)

français (FR) (109.55 KB - PDF)

**First published:**

23/08/2024

[View](/fr/documents/overview/zegalogue-epar-medicine-overview_fr.pdf)

hrvatski (HR) (129.21 KB - PDF)

**First published:**

23/08/2024

[View](/hr/documents/overview/zegalogue-epar-medicine-overview_hr.pdf)

italiano (IT) (106.71 KB - PDF)

**First published:**

23/08/2024

[View](/it/documents/overview/zegalogue-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (136.02 KB - PDF)

**First published:**

23/08/2024

[View](/lv/documents/overview/zegalogue-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (127.88 KB - PDF)

**First published:**

23/08/2024

[View](/lt/documents/overview/zegalogue-epar-medicine-overview_lt.pdf)

magyar (HU) (127.36 KB - PDF)

**First published:**

23/08/2024

[View](/hu/documents/overview/zegalogue-epar-medicine-overview_hu.pdf)

Malti (MT) (130.05 KB - PDF)

**First published:**

23/08/2024

[View](/mt/documents/overview/zegalogue-epar-medicine-overview_mt.pdf)

Nederlands (NL) (109.96 KB - PDF)

**First published:**

23/08/2024

[View](/nl/documents/overview/zegalogue-epar-medicine-overview_nl.pdf)

polski (PL) (131.43 KB - PDF)

**First published:**

23/08/2024

[View](/pl/documents/overview/zegalogue-epar-medicine-overview_pl.pdf)

português (PT) (109.51 KB - PDF)

**First published:**

23/08/2024

[View](/pt/documents/overview/zegalogue-epar-medicine-overview_pt.pdf)

română (RO) (125.95 KB - PDF)

**First published:**

23/08/2024

[View](/ro/documents/overview/zegalogue-epar-medicine-overview_ro.pdf)

slovenčina (SK) (129.14 KB - PDF)

**First published:**

23/08/2024

[View](/sk/documents/overview/zegalogue-epar-medicine-overview_sk.pdf)

slovenščina (SL) (127.17 KB - PDF)

**First published:**

23/08/2024

[View](/sl/documents/overview/zegalogue-epar-medicine-overview_sl.pdf)

Suomi (FI) (106.16 KB - PDF)

**First published:**

23/08/2024

[View](/fi/documents/overview/zegalogue-epar-medicine-overview_fi.pdf)

svenska (SV) (107.03 KB - PDF)

**First published:**

23/08/2024

[View](/sv/documents/overview/zegalogue-epar-medicine-overview_sv.pdf)

Zegalogue : EPAR - Risk management plan

English (EN) (599.24 KB - PDF)

**First published:** 23/08/2024

[View](/en/documents/rmp/zegalogue-epar-risk-management-plan_en.pdf)

## Product information

Zegalogue : EPAR - Product information

English (EN) (530.36 KB - PDF)

**First published:** 23/08/2024

**Last updated:** 22/04/2025

[View](/en/documents/product-information/zegalogue-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-290)

български (BG) (701.73 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/bg/documents/product-information/zegalogue-epar-product-information_bg.pdf)

español (ES) (533.57 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/es/documents/product-information/zegalogue-epar-product-information_es.pdf)

čeština (CS) (691.55 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/cs/documents/product-information/zegalogue-epar-product-information_cs.pdf)

dansk (DA) (576.74 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/da/documents/product-information/zegalogue-epar-product-information_da.pdf)

Deutsch (DE) (572.57 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/de/documents/product-information/zegalogue-epar-product-information_de.pdf)

eesti keel (ET) (524.17 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/et/documents/product-information/zegalogue-epar-product-information_et.pdf)

ελληνικά (EL) (704.11 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/el/documents/product-information/zegalogue-epar-product-information_el.pdf)

français (FR) (541.73 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/fr/documents/product-information/zegalogue-epar-product-information_fr.pdf)

hrvatski (HR) (668.8 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/hr/documents/product-information/zegalogue-epar-product-information_hr.pdf)

íslenska (IS) (565.5 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/is/documents/product-information/zegalogue-epar-product-information_is.pdf)

italiano (IT) (542.7 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/it/documents/product-information/zegalogue-epar-product-information_it.pdf)

latviešu valoda (LV) (700.42 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/lv/documents/product-information/zegalogue-epar-product-information_lv.pdf)

lietuvių kalba (LT) (665.8 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/lt/documents/product-information/zegalogue-epar-product-information_lt.pdf)

magyar (HU) (686.59 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/hu/documents/product-information/zegalogue-epar-product-information_hu.pdf)

Malti (MT) (700.31 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/mt/documents/product-information/zegalogue-epar-product-information_mt.pdf)

Nederlands (NL) (342.06 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/nl/documents/product-information/zegalogue-epar-product-information_nl.pdf)

norsk (NO) (485.16 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/no/documents/product-information/zegalogue-epar-product-information_no.pdf)

polski (PL) (692.03 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/pl/documents/product-information/zegalogue-epar-product-information_pl.pdf)

português (PT) (544.24 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/pt/documents/product-information/zegalogue-epar-product-information_pt.pdf)

română (RO) (703.53 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/ro/documents/product-information/zegalogue-epar-product-information_ro.pdf)

slovenčina (SK) (697.36 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/sk/documents/product-information/zegalogue-epar-product-information_sk.pdf)

slovenščina (SL) (685.5 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/sl/documents/product-information/zegalogue-epar-product-information_sl.pdf)

Suomi (FI) (467.78 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/fi/documents/product-information/zegalogue-epar-product-information_fi.pdf)

svenska (SV) (557.96 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/sv/documents/product-information/zegalogue-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000263475 22/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zegalogue : EPAR - All authorised presentations

English (EN) (14.88 KB - PDF)

**First published:** 23/08/2024

**Last updated:** 22/04/2025

[View](/en/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-47)

български (BG) (37.4 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/bg/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_bg.pdf)

español (ES) (33.44 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/es/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.23 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/cs/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.24 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/da/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.92 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/de/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.83 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/et/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.28 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/el/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_el.pdf)

français (FR) (14.86 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/fr/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (22.76 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/hr/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.11 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/is/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.36 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/it/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.8 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/lv/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.28 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/lt/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.05 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/hu/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.32 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/mt/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.19 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/nl/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.3 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/no/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.28 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/pl/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.42 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/pt/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.19 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/ro/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.76 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/sk/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.32 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/sl/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.96 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/fi/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.1 KB - PDF)

**First published:**

23/08/2024

**Last updated:**

22/04/2025

[View](/sv/documents/all-authorised-presentations/zegalogue-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zegalogue Active substance dasiglucagon hydrochloride International non-proprietary name (INN) or common name dasiglucagon Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code H04AA02

### Pharmacotherapeutic group

Pancreatic hormones

### Therapeutic indication

Zegalogue is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.

## Authorisation details

EMA product number EMEA/H/C/006214

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Novo Nordisk A/S

Novo Alle 1 DK-2880 Bagsvaerd Denmark

Opinion adopted 30/05/2024 Marketing authorisation issued 24/07/2024 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zegalogue : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.8 KB - PDF)

**First published:** 22/04/2025

[View](/en/documents/procedural-steps-after/zegalogue-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zegalogue : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (129.49 KB - PDF)

**First published:** 07/11/2024

**Last updated:** 22/04/2025

[View](/en/documents/procedural-steps-after/zegalogue-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Zegalogue : EPAR - Public assessment report

Adopted

Reference Number: EMA/281112/2024

English (EN) (9.26 MB - PDF)

**First published:** 23/08/2024

[View](/en/documents/assessment-report/zegalogue-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zegalogue

Reference Number: EMA/222106/2024

English (EN) (120.23 KB - PDF)

**First published:** 31/05/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zegalogue_en.pdf)

#### News on Zegalogue

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024) 31/05/2024

**This page was last updated on** 22/04/2025

## Share this page

[Back to top](#main-content)